Innovative Approaches Needed to Prevent Critical Infrastructure Failures, Arthur D. Little Blue Shift Report Finds
9.10.2025 11:00:00 EEST | Business Wire | Press release
Arthur D. Little (ADL)’s Blue Shift Institute today published Built to Last - Rethinking the Aging of Critical Infrastructure, an extensive new report that examines how to future-proof the essential infrastructure that underpins today’s societies.
Recent disruption caused by equipment failures such as electricity blackouts in Spain and Portugal and the shutdown of Heathrow Airport in the UK all demonstrate the pressing need to improve approaches for infrastructure management. Yet challenges around funding, technology and data all create major barriers that must be overcome.
Drawing on insights from over 20 industry leaders across energy, transportation, water, telecoms, and materials, the report examines how aging unfolds in complex, layered systems. It highlights the increasing pressures on infrastructure designed for 20th century needs that are now facing the challenge of 21st century usage. For example, nearly 70% of the US power grid is over 25 years old, according to the American Society for Civil Engineers.
The report outlines solutions for increasing resilience such as predictive tools, hybrid digital twins, and material and design innovations, along with the need for more collaborative ecosystems and partnerships to better manage risk at scale.
It demonstrates the requirement for new approaches that stop treating infrastructure as simple, isolated assets that degrade in a linear manner. Instead, they must be viewed as complex, layered, adaptive systems that are designed to evolve, adapt, and improve over time. It identifies 10 priorities for infrastructure leaders to address today’s realities and prepare for tomorrow’s uncertainties, including embedding aging scenarios in portfolio strategies and establishing interoperable data platfoms to integrate information from sensors, operations and external inputs.
Dr. Albert Meige, Global Director of Blue Shift at Arthur D. Little, comments: “Just as for humans, aging is unavoidable for the critical infrastructure that supports our lives. As our report demonstrates, simply continuing existing approaches to managing infrastucture is no longer sufficient. Innovation in aging is not just about resisting decay, but about designing systems to work with it, harnessing solutions from predictive maintenance to regenerative materials. Without this, we will face further major disruptions as infrastructure failure impact today’s complex, interconnected systems.”
The full reportcan be downloaded here: Built to last | Arthur D. Little
View source version on businesswire.com: https://www.businesswire.com/news/home/20251009983259/en/
Contacts
Cate Bonthuys
Catalyst Comms
+44 7715 817589
Bonthuys.Cate@adlittle.com
www.adlittle.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.adlittle.co
m&esheet=54336453&newsitemid=20251009983259&lan=en-US&anchor=www.adlittle.com&in
dex=2&md5=779b87d5885e3c3e5c19f2105e0e20dd
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom